García-Aranda Marilina, Téllez Teresa, Muñoz Miguel, Redondo Maximino
aDepartment of Biochemistry, REDISSEC, Hospital Costa del Sol, Marbella bResearch Laboratory of Neuropeptides, Virgen del Rocío University Hospital, Sevilla, Spain.
Anticancer Drugs. 2017 Aug;28(7):702-716. doi: 10.1097/CAD.0000000000000507.
Since its discovery in 1983, the protein clusterin (CLU) has been isolated from almost all human tissues and fluids and linked to the development of different physiopathological processes, including carcinogenesis and tumor progression. During the last few years, several studies have shown the cytoprotective role of secretory CLU in tumor cells, inhibiting their apoptosis and enhancing their resistance to conventional treatments including hormone depletion, chemotherapy, and radiotherapy. In an effort to determine the therapeutic potential that the inhibition of this protein could have on the development of new strategies for cancer treatment, numerous studies have been carried out in this field, with results, in most cases, satisfactory but sometimes contradictory. In this document, we summarize for the first time the current knowledge of the effects that CLU inhibition has on sensitizing tumor cells to conventional cancer treatments and discuss its importance in the development of new strategies against cancer.
自1983年被发现以来，蛋白簇集素（CLU）已从几乎所有人体组织和体液中分离出来，并与包括致癌作用和肿瘤进展在内的不同生理病理过程的发展相关联。在过去几年中，多项研究表明分泌型CLU在肿瘤细胞中具有细胞保护作用，可抑制其凋亡并增强其对包括激素剥夺、化疗和放疗在内的传统治疗的抗性。为了确定抑制该蛋白对开发癌症治疗新策略可能具有的治疗潜力，该领域已开展了大量研究，在大多数情况下结果令人满意，但有时也相互矛盾。在本文件中，我们首次总结了目前关于CLU抑制对使肿瘤细胞对传统癌症治疗敏感化的影响的认识，并讨论了其在开发抗癌新策略中的重要性。
